The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
The Significance of Chirality in Drug Design and Development
Open accessAbstract
Proteins are often enantioselective towards their binding partners. When designing small molecules to interact with these targets, one should consider stereoselectivity. As considerations for exploring structure space evolve, chirality is increasingly important. Binding affinity for a chiral drug can differ for diastereomers and between enantiomers. For the virtual screening and computational design stage of drug development, this problem can be compounded by incomplete stereochemical information in structure libraries leading to a "coin toss" as to whether or not the "ideal" chiral structure is present. Creating every stereoisomer for each chiral compound in a structure library leads to an exponential increase in the number of structures resulting in potentially unmanageable file sizes and screening times. Therefore, only key chiral structures, enantiomeric pairs based on relative stereochemistry need be included, and lead to a compromise between exploration of chemical space and maintaining manageable libraries. In clinical environments, enantiomers of chiral drugs can have reduced, no, or even deleterious effects. This underscores the need to avoid mixtures of compounds and focus on chiral synthesis. Governmental regulations emphasizing the need to monitor chirality in drug development have increased. The United States Food and Drug Administration issued guidelines and policies in 1992 concerning the development of chiral compounds. These guidelines require that absolute stereochemistry be known for compounds with chiral centers and that this information should be established early in drug development in order that the analysis can be considered valid. From exploration of structure space to governmental regulations it is clear that the question of chirality in drug design is of vital importance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21256 · Cited by 25,486
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929
Structural mechanism for statin inhibition of HMG-CoA reductase
Istvan, E. S., & Deisenhofer, J. (2001) · Science · doi:10.1126/science.1059344 · Cited by 1,644
Putting chirality to work: the strategy of chiral switches
Agranat, I., Caner, H., & Caldwell, J. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd915 · Cited by 637
Trends in the development of chiral drugs
Caner, H., Groner, E., Levy, L., & Agranat, I. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02904-0 · Cited by 399
Modeling water molecules in protein-ligand docking using GOLD.
Verdonk, M. L., Chessari, G., Cole, J. C., Hartshorn, M. J., Murray, C. W., Nissink, J. W. M., Taylor, R. D., & Taylor, R. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050543p · Cited by 393
Structure-based virtual screening of chemical libraries for drug discovery
Ghosh, S., Nie, A., An, J., & Huang, Z. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.04.002 · Cited by 246
Antidepressant specificity of serotonin transporter suggested by three LeuT–SSRI structures
Zhou, Z., Zhen, J., Karpowich, N. K., Law, C. J., Reith, M. E. A., & Wang, D.-N. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1602 · Cited by 240
Cited by
Contribution of Organofluorine Compounds to Pharmaceuticals
Inoue, M., Sumii, Y., & Shibata, N. (2020) · ACS Omega · doi:10.1021/acsomega.0c00830 · Cited by 1,944
Microbial lipases and their industrial applications: a comprehensive review
Chandra, P., Enespa, Singh, R., & Arora, P. K. (2020) · Microbial Cell Factories · doi:10.1186/s12934-020-01428-8 · Cited by 887
Assessing Atropisomer Axial Chirality in Drug Discovery and Development
LaPlante, S. R., Fader, L. D., Fandrick, K. R., Fandrick, D. R., Hucke, O., Kemper, R., Miller, S. P. F., & Edwards, P. J. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200584g · Cited by 861
The added value of small-molecule chirality in technological applications
Brandt, J. R., Salerno, F., & Fuchter, M. J. (2017) · Nature Reviews Chemistry · doi:10.1038/s41570-017-0045 · Cited by 781
Circularly polarized light detection using chiral hybrid perovskite
Chen, C., Gao, L., Gao, W., Ge, C., Du, X., Li, Z., Yang, Y., Niu, G., & Tang, J. (2019) · Nature Communications · doi:10.1038/s41467-019-09942-z · Cited by 589
Metadata
- Authors
- H. Brooks, W., C. Guida, W., & G. Daniel, K.
- Venue
- Current Topics in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-04-01
- Volume
- 11
- Issue
- 7
- Pages
- 760-770
- ISSN
- 1568-0266 (ISSN-L)
- OpenAlex
- W2158604280
- Cited by
- 694
- References
- 15
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Significance of Chirality in Drug Design and Development. https://app.cochat.ai/papers/10.2174/156802611795165098
- The paper
- H. Brooks, W., C. Guida, W., & G. Daniel, K. (2011). The Significance of Chirality in Drug Design and Development. Current Topics in Medicinal Chemistry. https://doi.org/10.2174/156802611795165098
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.